Aggrenox
NDC 21695-656

View dosage, usage, ingredients, routes, and UNII mappings.
Table of Contents
  1. Product Information
  2. Product Packages
  3. Product Characteristics
  4. What is NDC 21695-656?
  5. Aggrenox Uses
  6. Active Ingredients UNII Codes
  7. Inactive Ingredients UNII Codes
  8. NDC to RxNorm Crosswalk

Product Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Aggrenox is a NDA-approved product labeled by Rebel Distributors Corp.. This medication is used to reduce the risk of stroke in patients who have had "mini-strokes" (transient ischemic attacks) or a previous stroke due to a blood clot and are at high risk for another stroke. It is supplied as a red product. This product entry covers the primary NDC 21695-656 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.

Primary Identification

NDC Product Code:
21695-656
Proprietary Name:
Aggrenox
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:

Labeler & Regulatory Data

Labeler Name: [5]
Rebel Distributors Corp.
Labeler Code:
21695
Product Label ID:
6473563d-b4df-4434-a74e-f8fa3cb9994f
FDA Application Number: [6]
NDA020884
Marketing Category: [8]
NDA - A product marketed under an approved New Drug Application.

Marketing Timeline

Start Marketing Date: [9]
12-19-1999
Listing Expiration Date: [11]
12-31-2017
Exclude Flag: [12]
I

Product Characteristics

Color(s):
RED (C48326 - RED)
WHITE (C48325 - IVORY)
Shape:
CAPSULE (C48336)
Size(s):
24 MM
Imprint(s):
BI;01A
Score:
1

Code Structure Chart

Product Details

What is NDC 21695-656?

The NDC code 21695-656 is assigned by the FDA to the product Aggrenox. This pharmaceutical product is labeled by Rebel Distributors Corp. and is currently categorized as listed product. In terms of distribution, this product is available in a single package configuration. The associated package NDC(s) include: 21695-656-60. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.

What are the uses of this product?

This medication is used to reduce the risk of stroke in patients who have had "mini-strokes" (transient ischemic attacks) or a previous stroke due to a blood clot and are at high risk for another stroke. It contains two medications: a very low dose of aspirin (25 milligrams per tablet) and dipyridamole in a slow-release form. Low-dose aspirin and dipyridamole are antiplatelet drugs that work to keep blood flowing to the brain by stopping platelets from clumping together. This helps prevent the platelets from forming blood clots, which can lodge in the brain and cause a certain type of stroke (ischemic stroke).

Which are the associated UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are the Inactive Ingredients associated UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for this product?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 1362082 - Aggrenox 25 MG / 200 MG 12HR Extended Release Oral Capsule
  • RxCUI: 1362082 - 12 HR aspirin 25 MG / dipyridamole 200 MG Extended Release Oral Capsule [Aggrenox]
  • RxCUI: 1362082 - 12 HR ASA 25 MG / Dipyridamole 200 MG Extended Release Oral Capsule [Aggrenox]
  • RxCUI: 1362082 - Aggrenox 25/200 (aspirin 25 MG / dipyridamole 200 MG) 12HR Extended Release Oral Capsule
  • RxCUI: 1362082 - Aggrenox 25/200 12HR Extended Release Oral Capsule

* Please review the full disclaimer at the bottom of this page.

Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".